CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will host a conference call to discuss the preliminary data from its Phase II study of ALN-RSV01, an RNAi therapeutic in development for the treatment of respiratory syncytial virus (RSV) infection, which is being developed in collaboration with Cubist Pharmaceuticals, Inc. A senior scientific representative from Cubist will also be on the call, which will be held on Monday, June 8, 2009 at 8:30 a.m. ET.
